Does E71.310 require prior authorization?

No, E71.310 does not require prior authorization (high confidence). Covered without prior authorization.

Backwork Sign up free

`E71.310`, Long chain/very long chain acyl CoA dehydrogenase deficiency

ICD-10-CM

Prior Authorization

No Prior Auth Required

Covered without prior authorization (high confidence)

Documentation Required

Rigorous clinical evaluation should precede diagnostic molecular testing.
Disease-specific diagnostic criteria or clinical findings as listed throughout the policy must be documented (e.g., Amsterdam II or revised Bethesda for Lynch syndrome; Schwartz score for LQTS; clinical criteria for Marfan Syndrome [see Appendix]; clinical features lists for Angelman, Prader-Willi, CADASIL, etc.).
For general medical necessity: documentation that all of the following are met: The member displays clinical features, or is at direct risk of inheriting the mutation (pre-symptomatic); and The result of the test will directly impact the treatment being delivered to the member; and After history, physical examination, pedigree analysis, genetic counseling, and completion of conventional diagnostic studies, a definitive diagnosis remains uncertain and a suspected diagnosis is listed; and Disease-specific criteria met.

Key Coverage Criteria

Loeys-Dietz syndrome (TGFBR1, TGFBR2): Testing medically necessary when: asymptomatic individual has affected first-degree relative with known deleterious mutation (test for familial mutation); or to confirm diagnosis in individual with LDS characteristics (begin with TGFBR2 sequencing, then TGFBR1 if negative).
I42.0 Dilated cardiomyopathy [hereditary]
I49.01 Ventricular fibrillation
I71.01 Dissection of thoracic aorta
Von Hippel-Lindau syndrome (VHL)
Walker-Warburg syndrome (POMGNT1)

1 Active Policy

AETNA-CPB-0140, Genetic Testing

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about E71.310 Sign up free

For whole exome sequencing: documentation that member and family history have been evaluated by a Board-Certified or Board-Eligible Medical Geneticist; member receives pre- and post-test counseling by an independent provider (e.g., ABMG or ABGC-certified Genetic Counselor or APGN credentialed by GNCC or ANCC); alternate etiologies considered and ruled out when possible; clinical presentation does not fit a well-described syndrome for which single-gene/panel testing is available; WES more efficient than separate single-gene tests/panels; diagnosis cannot be made by standard clinical work-up (excluding invasive procedures); documentation that WES is predicted to have impact on health outcomes (treatment, surveillance, palliative care, reduce diagnostic uncertainty, or inform reproductive counseling).

E71.310, Long chain/very long chain acyl CoA dehydrogenase deficiency